News
About HeMo Bioengineering
我们已于中国及广泛亚太地区建立全套针对神经血管及外周疾病的创新介入医疗器械。我们的神经介入医疗器械的全面产品组合涵盖所有缺血性脑卒中、出血性脑卒中及神经通路领域,而我们率先上市的国内抽吸导管Afentta足以证明这一点。我们是中国急性缺血性脑卒中机械取栓术的先驱。我们的主要产品之一Afentta颅内血栓抽吸导管是第一个获得国家药监局批准及于中国商业化的国内抽吸导管。我们的其他主要产品 088型号HMC1-NAS颅内血栓抽吸导管一旦获批,可能是全球市场上各抽吸导管中具备全球最大远端内径的抽吸导管。此外,我们的外周介入医疗器械覆盖血管及非血管介入领域。我们的核心产品 Privi痔疮冷却球囊是一个仅采用物理机制治疗痔疮,无需可能与副作用相关的药物或成分的非血管介入医疗器械。截至最后实际可行日期,我们拥有三种已商业化的产品、四种额外批准产品、三种处于注册审查或临床试验阶段的在研产品,以及十二种处于临床前阶段的在研产品。
More
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.